Trinity Biotech (TRIB) Cost of Revenue (2009 - 2024)

Trinity Biotech's Cost of Revenue history runs 16 years deep, the most recent figure standing at $11.0 million for Q4 2024.

• In Q4 2024, Cost of Revenue rose 23.91% year-over-year to $11.0 million; the TTM figure through Dec 2024 stood at $40.1 million (up 7.31% YoY), while the FY2025 annual figure was $26.9 million, down 32.95% from the prior year.
• Cost of Revenue came in at $11.0 million for Q4 2024 at Trinity Biotech, up from $9.8 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $17.1 million in Q4 2020 to a low of $8.9 million in Q4 2023.
• A 5-year average of $11.6 million and a median of $10.4 million in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 61.87% in 2021 and slumped 33.98% in 2022, its largest moves.
• Trinity Biotech's Cost of Revenue stood at $17.1 million in 2020, then dropped by 28.19% to $12.3 million in 2021, then retreated by 15.76% to $10.4 million in 2022, then slipped by 14.39% to $8.9 million in 2023, then grew by 23.91% to $11.0 million in 2024.
• According to Business Quant data, Cost of Revenue over the past three periods registered $11.0 million, $9.8 million, and $10.1 million for Q4 2024, Q3 2024, and Q2 2024 respectively.

Peer Comparison